Source: Annual Congress 2006 - COPD world-wide
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Stenfors (Ostersund, Sweden). Physician-diagnosed COPD GOLD stage IV in Östersund, Sweden: prevalence and patient characteristics. Eur Respir J 2006; 28: Suppl. 50, 2601

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of co-morbidities in Greek COPD patients in relation to the stage of the disease (COMPACT study) Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017 The prevalence of QTc-prolongation increase by GOLD stage in COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017 COPD GOLD stage 1: Is it really a disease? Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Impact of comorbidities on survival of patients with COPD according to GOLD stages Source: Annual Congress 2011 - COPD: burden of disease, imaging and management Year: 2011 GOLD stage 0 and risk of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 352s Year: 2003 Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population Source: International Congress 2018 – Interdependence of COPD and comorbidities and the underlying mechanisms Year: 2018 Comorbidities in stage IV COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: A national cross-sectional survey Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Three year follow-up of distribution and stability of patients with COPD according GOLD 2014 Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 High prevalence of osteoporosis in COPD patients independent of GOLD stage Source: Annual Congress 2010 - What's new in pulmonary rehabilitation and chronic care in 2010 Year: 2010 Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results Source: Eur Respir J 2005; 26: Suppl. 49, 69s Year: 2005 High risk COPD patients cost less if treated according to GOLD 2011 recommendations Source: Annual Congress 2013 –COPD diagnosis Year: 2013 COPD comorbidities and risk assessment according to GOLD 2011 revision Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Prevalence and severity of GOLD defined COPD in adults Source: Eur Respir J 2002; 20: Suppl. 38, 123s Year: 2002 Survival in three years of COPD patients according to GOLD 2003 and GOLD 2014 Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases Year: 2015 GOLD and phenotypes: The new Czech COPD guidelines Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Heterogeneity of group D in the new GOLD classification of COPD Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Cardiovascular diseases (CVD), arterial hypertension (AH) and diabetes mellitus (DM) in a cohort of 609 COPD patients: Associations with the new GOLD classification 2011 Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018